Answers are grounded in this paper and cite their sources.
Objective This study evaluated changes in inflammatory and neurogenic biomarkers in nasal secretions in relation to clinical outcomes following temperature‐controlled radiofrequency ( TCRF) posterior nasal nerve (PNN) ablation in patients with allergic ( AR ) and nonallergic ( NAR ) chronic rhinitis (CR) . Methods In this prospective multicenter study, 25 participants with moderate to severe CR underwent TCRF PNN ablation. Nasal secretions were collected at baseline and 3 months postprocedure and analyzed for inflammatory biomarkers ( ECP , EGF , IFNγ , IgE , IL ‐1β, IL ‐4, IL ‐5, IL ‐6, IL ‐8, IL ‐10, IL ‐13, IL ‐ 17A , IL ‐ 17F , IL ‐22, IL ‐25, TNFα ) and TRPV1 , a sensory nerve marker. Reflective total nasal symptom scores ( rTNSS ) were assessed from baseline through 6 months. Results Mean rTNSS decreased from 7.8 (95% CI: 7.0 to 8.7) at baseline to 4.3 (95% CI: 3.2 to 5.4) at 3 months, a 46% improvement; 75% of participants met responder criteria. Reductions were observed in TRPV1 (0.76‐fold) and in epithelial derived IL ‐25 (0.89‐fold) across AR and NAR patients. Reductions in IL ‐8 were associated with greater treatment response. Conclusions TCRF PNN ablation was associated with symptom improvement in both AR and NAR patients with reduction in neurogenic and epithelial biomarkers, including TRPV1 and IL ‐25. These findings provide preliminary evidence that TCRF PNN ablation may be a neuroimmune modulatory therapy for CR . Level of Evidence 3. Trial Registration ClinicalTrials.gov (NCT06599736)
No takes yet. Share an insight, caveat, or question.
Toskala et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: